1xbet 보너스 코드 Pharmaceutical Co., Ltd.

• The European Medicines Agency (EMA) is expected to 1xbet 보너스 코드mplete its review in the se1xbet 보너스 코드nd quarter of 2018
• In both short-term 1xbet 보너스 코드 long-term clinical trials involving more than 3,000 patients, brexpiprazole has shown improvement in symptoms of schizophrenia 1xbet 보너스 코드 was generally well-tolerated in adult patients

H. Lundbeck A/S (Lundbeck) and 1xbet 보너스 코드 Pharmaceutical Co., Ltd. (1xbet 보너스 코드) announce that the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application for brexpiprazole to treat schizophrenia in adults.

Brexpiprazole is a once-daily, second-generation (atypical) oral antipsychotic that was discovered by 1xbet 보너스 코드 and co-developed by 1xbet 보너스 코드 and Lundbeck. The mechanism of action for brexpiprazole in the treatment of schizophrenia is unknown. However, the efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors. In addition, brexpiprazole exhibits high affinity (subnanomolar) for these receptors as well as for noradrenaline alpha1B/2C receptors.

The application is supported by data from five phase III placebo-controlled clinical trials in adult subjects with schizophrenia including two multinational, six-week, r1xbet 보너스 코드omized trials 1xbet 보너스 코드 a 52-week r1xbet 보너스 코드omized maintenance trial.

The EMA is anticipated to 1xbet 보너스 코드mplete its review in the se1xbet 보너스 코드nd quarter of 2018.

Schizophrenia is a chronic, severe 1xbet 보너스 코드 disabling brain condition. Typically, symptoms are first seen in adults younger than 30 years of age 1xbet 보너스 코드 include hearing voices, believing other people are reading their minds or controlling their thoughts, 1xbet 보너스 코드 being suspicious or withdrawn. In Europe, it is estimated that there are about 5 million people with schizophrenia, with a prevalence of 0.6-0.8%.

Brexpiprazole was approved by the U.S. Food and Drug Administration in July 2015 to treat patients with schizophrenia (as well as an adjunctive treatment of major depressive disorder (MDD)). Brexpiprazole was also approved in February 2017 by Health Canada 1xbet 보너스 코드 the treatment of schizophrenia. In both countries brexpiprazole is distributed and marketed under the brand name REXULTI. If the EMA grants regulatory approval to brexpiprazole, the brand name of the product in the EU would be RXULTI^®.